Betterchem
Health     Industry Portals     News     For Consumers     21CFR     Search     Site Map

 
IMATINIB

 
 
Content specific to this active ingredient…

Drug Information
Prescribing and patient information from leading authorities

Drug Master Files
Type 2 master files on file at the FDA

Drug Recalls
For prescription drugs containing this active ingredient

Exclusivity
Patent and market exclusivity data

Federal Register
FR search results for this API

FDA Approved Labelling
Information found in this drug's package inserts

Research Links
Chemical identification and research citations

Title 21 Code of Federal Regulations
FDA regulations for this API

   

 


 

FDA Approval Activities for this Drug…

Gleevec (imatinib mesylate) capsules, 100 mg, Novartis NDA 21-335/S-004 12/20/02 1/29/03 12/23/02 7/8/03 Gleevec (imatinib mesylate) capsules, 50 mg and 100 mg, Novartis NDA 21-335/S-003 5/20/03 7/24/03 Gleevec (imatinib mesylate) capsules, 50 mg and 100 mg, Novartis NDA 21-335/S-001 2/1/02 2/1/02 2/1/02 7/8/03 Gleevec Indication: This supplement added an indication for Gastrointestinal Stromal Tumors (GIST) Gleevec (imatinib mesylate) capsules, 50 mg and 100 mg, Novartis NDA 21-335 5/10/01 5/11/01 5/11/01 10/17/01 Gleevec Indication: for the treatment of patients with chronic myeloid leukemia (CML) in blast crisis, accelerated phase, or in chronic phase after failure of interferon-alpha therapy. Gleevec (imatinib mesylate) Tablets, 100 and 400 mg, Novartis NDA 21-588 Gleevec (imatinib mesylate) Tablets, Novartis Pharmaceuticals 21-588/S-002, S-003 | Gleevec (imatinib mesylate) Tablets, Novartis Pharma, Efficacy Supplement w/Data to Support | Gleevec (imatinib mesylate) Tablets, Novartis Pharma, Control Supplement & Labeling Revision | Gleevec (imatinib mesylate) Tablets, Novartis Pharma, Efficacy Supplement w/Clinical Data | Gleevec (imatinib mesylate) Tablets, Novartis Pharma, Labeling Revision | Gleevec (imatinib mesylate) Tablets, Novartis Pharma, New or Modified Indication | Gleevec (imatinib mesylate) Tablets, Novartis Pharma, New or Modified Indication | Gleevec (imatinib mesylate) Tablets, Novartis Pharma, Labeling Revision | Gleevec (imatinib mesylate) Tablets, Novartis Pharma, Efficacy Suppl. w/Clinical Data | Gleevec (imatinib mesylate) Tablets, Novartis Pharmaceuticals, Package Change | Gleevec (imatinib mesylate) Tablets, Novartis Pharmaceuticals Corp., Labeling Revision | Gleevec (imatinib mesylate) Tablets, Novartis Pharmaceuticals Corp., Labeling Revision

^ FDA's latest approval appears at the bottom of this list. ^


 

A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U-Z

Health Topics | News Feed for each API | DMF Index | Pharma Job Search | Pharma Company News

© 2008 Betterchem.com